Rani Therapeutics Holdings, Inc. reports developments tied to its clinical-stage biotherapeutics platform for oral delivery of biologics and drugs. The company’s RaniPill® capsule technology is designed to deliver drug substances such as antibodies, proteins, peptides and oligonucleotides as an alternative to subcutaneous injection or intravenous infusion.
Recurring RANI news includes clinical and preclinical updates for RaniPill-based programs, including RT-114, a GLP-1/GLP-2 dual agonist program for obesity, and oral semaglutide work. Company updates also cover financial results, collaboration and license activity, private placement financing, manufacturing and supply-chain capabilities, pipeline prioritization, investor conference participation, and leadership or advisory appointments supporting platform and clinical strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Rani Therapeutics, a clinical-stage biotherapeutics company, announced that its CEO, Talat Imran, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 11:30 AM ET. The event will showcase Rani's innovative approach to oral delivery of biologics and drugs, primarily through its patented RaniPill® capsule technology, which aims to replace traditional injection methods. Interested parties can access the live webcast from the Investor Relations section of Rani Therapeutics' website, with a replay available post-event.
Rani Therapeutics is dedicated to enhancing drug delivery systems and has successfully conducted multiple preclinical and clinical studies to validate the safety and efficacy of its oral dosing technologies.
Rani Therapeutics, a clinical-stage biotherapeutics company, announced that CEO Talat Imran will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 12:45 p.m. PT / 3:45 p.m. ET. The presentation will focus on Rani's innovative RaniPill capsule technology, designed to facilitate the oral delivery of biologics and drugs, potentially replacing subcutaneous and intravenous methods. Interested individuals can access the live webcast via Rani's Investor Relations page, with replays available for approximately 90 days post-event. Rani Therapeutics is committed to advancing oral drug delivery technologies and has successfully completed multiple studies to assess the safety and efficacy of its RaniPill platform.
Rani Therapeutics Holdings (RANI) announced significant advancements in its pipeline, including the anticipated initiation of its first Phase 2 study for RT-102 targeting osteoporosis in 2H 2023. The company reported positive topline results from a Phase 1 repeat-dose study of RT-102, achieving all endpoints. Moreover, initial feedback from the FDA suggests a suitable 505(b)(2) pathway for RT-102's development. A partnership with Celltrion has been established to advance the RT-111 program, an oral ustekinumab biosimilar. Financially, Rani reported a net loss of $63.3 million for 2022, an increase from $53.1 million in 2021, with cash reserves of $98.5 million expected to support operations through mid-2024.